High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis
10.3988/jcn.2019.15.4.454
- Author:
Su Hyun KIM
1
;
Yeseul KIM
;
Ji Yun JUNG
;
Na Young PARK
;
Hyunmin JANG
;
Jae Won HYUN
;
Ho Jin KIM
Author Information
1. Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. hojinkim@ncc.re.kr
- Publication Type:Original Article
- Keywords:
John Cunningham virus;
antibodies;
index;
progressive multifocal leukoencephalopathy;
Asia
- MeSH:
Antibodies;
Asia;
Asian Continental Ancestry Group;
Enzyme-Linked Immunosorbent Assay;
Humans;
JC Virus;
Leukoencephalopathy, Progressive Multifocal;
Multiple Sclerosis;
Natalizumab;
Seroepidemiologic Studies
- From:Journal of Clinical Neurology
2019;15(4):454-460
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS. METHODS: The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients. RESULTS: The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52–4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years). CONCLUSIONS: The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.
